Quote this publication Share Print

XARELTO

-
Opinions on drugs - Posted on Nov 10 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance (packages of 5, 10 and 30 tablets) and approved for use by hospitals (packages of 5, 10, 30 and 100 tablets).

-


Clinical Benefit

Substantial

The actual benefit of XARELTO 10 mg tablets is substantial.


Clinical Added Value

minor

XARELTO 10 mg tablets provides a minor improvement in actual benefit (IAB IV) in terms of efficacy compared with LOVENOX (enoxaparin) for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.


Contact Us

Évaluation des médicaments

See also